CDXS | Codexis, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.30 - 4.69
52 Week Range	1.8500 - 4.91
Beta	2.01
Implied Volatility	74.57%
IV Rank	22.49%
Day's Volume	676,827
Average Volume	655,703
Shares Outstanding	81,377,800
Market Cap	375,151,658
Sector	Healthcare
Industry	Biotechnology
IPO Date	2010-04-22

Valuation
Profitability
Growth
Health
P/E Ratio	-5.24
Forward P/E Ratio	-5.16
EPS	-0.88
1YR Price Target	14.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	174
Country	USA
Website	CDXS

Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases, etc. The company operates in two business segments namely Performance Enzymes and Novel Biotherapeutics. It generates maximum revenue from the Performance Enzymes segment.

CDXS's peers: NUVB, LYEL, IPSC, GBIO, STTK, FHTX, GLUE, KYMR, NRIX, KZR, MLYS, NKTX, NGM, CGEM, THRX, RVMD

*Chart delayed

Analyzing fundamentals for CDXS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see CDXS Fundamentals page.

Watching at CDXS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CDXS Technicals page.